1. Home
  2. FLGT vs TBPH Comparison

FLGT vs TBPH Comparison

Compare FLGT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLGT
  • TBPH
  • Stock Information
  • Founded
  • FLGT 2011
  • TBPH 2013
  • Country
  • FLGT United States
  • TBPH United States
  • Employees
  • FLGT N/A
  • TBPH N/A
  • Industry
  • FLGT Medical Specialities
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • FLGT Health Care
  • TBPH Health Care
  • Exchange
  • FLGT Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • FLGT 697.3M
  • TBPH 699.0M
  • IPO Year
  • FLGT 2016
  • TBPH N/A
  • Fundamental
  • Price
  • FLGT $30.25
  • TBPH $20.01
  • Analyst Decision
  • FLGT Buy
  • TBPH Strong Buy
  • Analyst Count
  • FLGT 3
  • TBPH 4
  • Target Price
  • FLGT $28.33
  • TBPH $28.00
  • AVG Volume (30 Days)
  • FLGT 411.7K
  • TBPH 597.9K
  • Earning Date
  • FLGT 11-07-2025
  • TBPH 11-10-2025
  • Dividend Yield
  • FLGT N/A
  • TBPH N/A
  • EPS Growth
  • FLGT N/A
  • TBPH N/A
  • EPS
  • FLGT N/A
  • TBPH 0.58
  • Revenue
  • FLGT $315,549,000.00
  • TBPH $80,327,000.00
  • Revenue This Year
  • FLGT $15.19
  • TBPH $79.82
  • Revenue Next Year
  • FLGT $10.58
  • TBPH N/A
  • P/E Ratio
  • FLGT N/A
  • TBPH $34.40
  • Revenue Growth
  • FLGT 13.61
  • TBPH 27.12
  • 52 Week Low
  • FLGT $14.57
  • TBPH $7.90
  • 52 Week High
  • FLGT $31.04
  • TBPH $20.28
  • Technical
  • Relative Strength Index (RSI)
  • FLGT 71.79
  • TBPH 73.27
  • Support Level
  • FLGT $28.65
  • TBPH $17.50
  • Resistance Level
  • FLGT $31.04
  • TBPH $18.58
  • Average True Range (ATR)
  • FLGT 1.33
  • TBPH 1.03
  • MACD
  • FLGT 0.21
  • TBPH 0.21
  • Stochastic Oscillator
  • FLGT 87.98
  • TBPH 94.28

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: